title: [Biologically active substances during treatment of pulmonary hypertension with ATP infusions immediately after general anesthesia and surgery of hypervolemic congenital heart defects].
abstract: In 95 patients with hypervolemic congenital heart valve defects (42 with interventricular and interatrial septal defects, and 53 with patent ductus arteriosus) mixed venous blood levels of serotonin, histamine, adrenalin, noradrenaline, total 11-hydroxycorticosteroids were studied using spectrofluorimetry, cyclic adenosine- and guanosine monophosphate (cAMP and cGMP), prostaglandins E + A and F2 alpha and their interaction were assessed using radioimmunoassay and correlation analysis, respectively. Immediately after general anesthesia and surgical correction of septal defects using cardiopulmonary bypass adrenalin level was increased, while noradrenaline, cAMP, cGMP, prostaglandin E + A levels remained high. Similar pattern was observed in patients after arterial duct ligation. Mean pulmonary artery pressure was elevated in both groups of patients (above 4 kPa). Effective therapy of pulmonary hypertension with intravenous ATP infusions immediately after general anesthesia and elimination of septal defects (20 patients) was accompanied by a decline in noradrenaline, cGMP and total 11-hydroxycorticosteroid level (with adrenalin level increased), while after open arterial duct ligation (20 patients) it was followed by a drop in noradrenaline and prostaglandin F2 alpha level (with adrenalin level increased) and the activation of the interaction of biologically active substances aimed predominantly at attenuation of vasoconstrictor reactions in the lungs.
authors.forename: N M
authors.initials: NM
authors.lastname: Gerasimov
authors.forename: D S
authors.initials: DS
authors.lastname: Guliamov
authors.forename: T Z
authors.initials: TZ
authors.lastname: Karimova
authors.forename: O A
authors.initials: OA
authors.lastname: Belova
authors.forename: L S
authors.initials: LS
authors.lastname: Ivanova
authors.forename: L N
authors.initials: LN
authors.lastname: Nam
mesh_terms: D015062:11-Hydroxycorticosteroids / Q000097:blood*; D000255:Adenosine Triphosphate / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000768:Anesthesia, General; D001810:Blood Volume; D002395:Catecholamines / Q000097:blood*; D002648:Child; D000242:Cyclic AMP / Q000097:blood*; D006152:Cyclic GMP / Q000097:blood*; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007262:Infusions, Intravenous; D008297:Male; D011453:Prostaglandins / Q000097:blood*; D013997:Time Factors
chemical_list: D015062:11-Hydroxycorticosteroids; D002395:Catecholamines; D011453:Prostaglandins; D000255:Adenosine Triphosphate; D000242:Cyclic AMP; D006152:Cyclic GMP
vernacular_title: Biologicheski aktivnye veshchestva v usloviiakh terapii legochnoĭ gipertenzii infuziiami ATF v blizhaĭshem periode posle obshcheĭ anestezii i likvidatsii gipervolemicheskikh vrozhdennykh porokov serdtsa.